Author Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results

Affiliations

• ¹ Department of Pediatrics, Center for Advanced Innate Cell Therapy, Baylor College of Medicine, Houston, TX, USA. heczey@bcm.edu.
• ² Department of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA. heczey@bcm.edu.
• ³ Department of Pediatrics, Center for Advanced Innate Cell Therapy, Baylor College of Medicine, Houston, TX, USA.
• ⁴ Department of Radiology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.
• ⁵ Department of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.
• ⁶ Biostatistics and Data Management Resource, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
• ⁷ Department of Pediatrics, Cincinnati Children's Hospital, Cincinnati, OH, USA.
• ⁸ Immunai, Inc., New York, NY, USA.
• ⁹ Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
• ¹⁰ Department of Pediatrics, Center for Advanced Innate Cell Therapy, Baylor College of Medicine, Houston, TX, USA. lsmeteli@txch.org.
• ¹¹ Department of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA. lsmeteli@txch.org.